Search results for " Vaccines"

showing 10 items of 472 documents

In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthroug…

2022

AbstractSince neutrophil extracellular traps formation (NET-osis) can be assessed indirectly by treating healthy neutrophils with blood-derived fluids from patients and then measuring the NETs response, we designed a pilot study to convey high-dimensional cytometry of peripheral blood immune cells and cytokines, combined with clinical features, to understand if NET-osis assessment could be included in the immune risk profiling to early prediction of clinical patterns, disease severity, and viral clearance at 28 days in COVID-19 patients. Immune cells composition of peripheral blood, cytokines concentration and in-vitro NETosis were detected in peripheral blood of 41 consecutive COVID-19 inp…

CD4-Positive T-LymphocytesMultidisciplinaryCOVID-19 VaccinesInterleukin-6SARS-CoV-2COVID-19 VaccineCOVID-19Pilot ProjectsCD8-Positive T-LymphocyteLeukocyte Common AntigenCD8-Positive T-LymphocytesCOVID-19 Drug TreatmentCD4-Positive T-LymphocyteCytokinesHumansLeukocyte Common AntigensPilot ProjectCytokine
researchProduct

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

2015

Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the …

CD4-Positive T-LymphocytesT cellmedicine.medical_treatmentMelanoma ExperimentalEpitopes T-LymphocyteMajor histocompatibility complexCancer VaccinesArticleEpitopeMiceImmune systemAntigenCancer immunotherapymedicineAnimalsHumansCytotoxic T cellComputer SimulationExomePrecision MedicineMultidisciplinarybiologyHistocompatibility Antigens Class IISequence Analysis DNAImmunotherapySurvival AnalysisDisease Models Animalmedicine.anatomical_structureMutationImmunologybiology.proteinFemaleImmunotherapyAlgorithmsNature
researchProduct

Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.

2005

Abstract Quantitative evaluation of T cell responses of patients receiving antitumoral vaccination with a protein is difficult because of the large number of possible HLA-peptide combinations that could be targeted by the response. To evaluate the responses of patients vaccinated with protein MAGE-3, we have developed an approach that involves overnight stimulation of blood T cells with autologous dendritic cells loaded with the protein, sorting by flow cytometry of the T cells that produce IFN-γ, cloning of these cells, and evaluation of the number of T cell clones that secrete IFN-γ upon stimulation with the Ag. An important criterion is that T cell clones must recognize not only stimulat…

CD4-Positive T-Lymphocytesmedicine.medical_treatmentT cellImmunologyAntigen presentationMolecular Sequence DataCD4 T cellsCell SeparationBiologyLymphocyte ActivationCancer VaccinesFlow cytometryInterleukin 21Interferon-gammaAntigenSDG 3 - Good Health and Well-beingAntigens NeoplasmMonitoring ImmunologicmedicineTumor Cells CulturedImmunology and AllergyHumansAmino Acid SequenceLymphocyte CountMelanomaCell Line TransformedAntigen Presentationmedicine.diagnostic_testT-cell receptorCoculture TechniquesGrowth InhibitorsClone CellsNeoplasm Proteinsmedicine.anatomical_structureCell cultureImmunologyAdjuvantVaccineMAGE-3 proteinJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM …

2020

Abstract Objectives To evaluate the strength of association between maternal and pregnancy characteristics and the risk of adverse perinatal outcomes in pregnancies with laboratory confirmed COVID-19. Methods Secondary analysis of a multinational, cohort study on all consecutive pregnant women with laboratory-confirmed COVID-19 from February 1, 2020 to April 30, 2020 from 73 centers from 22 different countries. A confirmed case of COVID-19 was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The primary outcome was a composite adverse fetal outcome, defined as the presence of either abortion (pre…

COVID-19 VaccineInfectious Disease TransmissionPerinatal DeathAbortionClinical Laboratory TechniqueMiscarriageCohort Studies0302 clinical medicineCOVID-19 TestingPregnancyRisk Factors3123 Gynaecology and paediatricsSecondary analysisPerinatal medicineAbortion SpontaneouMedicineVertical030212 general & internal medicineViralPregnancy Complications Infectiouscoronavirus; perinatal morbidity; perinatal mortality; covid-19Coronavirus; perinatal morbidity; perinatal mortality; Abortion Spontaneous; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Cohort Studies; Coronavirus Infections; Female; Gestational Age; Humans; Infant Newborn; Infant Premature; Infectious Disease Transmission Vertical; Pandemics; Pneumonia Viral; Pregnancy; Pregnancy Complications Infectious; Pregnancy Outcome; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; SARS-CoV-2; Betacoronavirus; Fetal Death; Perinatal Deathperinatal morbidity030219 obstetrics & reproductive medicineObstetricsReverse Transcriptase Polymerase Chain ReactionInfectiousPregnancy OutcomeGestational ageObstetrics and Gynecology3. Good healthSettore MED/40perinatal mortalityGestationFemaleCoronavirus InfectionsInfant PrematureHumanmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)CoronaviruPneumonia ViralSocio-culturaleGestational AgeIntrauterine deviceCoronavirus; perinatal morbidity; perinatal mortality03 medical and health sciencesBetacoronavirusPARVOVIRUS B19 INFECTIONCoronavirus perinatal morbidity perinatal mortalityHumansAdverse effectPrematurePandemicsFetal DeathPregnancyFetusBetacoronaviruPandemicCoronavirus Infectionbusiness.industryClinical Laboratory TechniquesSARS-CoV-2Risk FactorSpontaneousMORTALITYInfant NewbornAbortionCOVID-19InfantOdds ratioPneumoniamedicine.diseaseNewbornInfectious Disease Transmission VerticalAbortion SpontaneousPregnancy ComplicationsCoronavirusPediatrics Perinatology and Child HealthPregnancy Complications InfectiouCohort StudiebusinessCoronavirus; perinatal mortality; perinatal morbidityJournal of perinatal medicine
researchProduct

Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study

2022

To date there has been limited head-to-head evaluation of immune responses to different types of COVID-19 vaccines. A real-world population-based longitudinal study was designed with the aim to define the magnitude and duration of immunity induced by each of four different COVID-19 vaccines available in Italy at the time of this study. Overall, 2497 individuals were enrolled at time of their first vaccination (T0). Vaccine-specific antibody responses induced over time by Comirnaty, Spikevax, Vaxzevria, Janssen Ad26.COV2.S and heterologous vaccination were compared up to six months after immunization. On a subset of Comirnaty vaccinees, serology data were correlated with the ability to neutr…

COVID-19 VaccinesAd26COVS1vaccines.SARS-CoV-2ImmunologyCOVID-19serologyViral VaccinesvaccinesHumansB-cell memory; COVID-19; cell-mediated immunity; serology; vaccinescell-mediated immunityImmunology and AllergyB-CELL MEMORY COVID-19 CELL-MEDIATED IMMUNITY SEROLOGY VACCINESB-cell memoryLongitudinal StudiesB-cell memory; COVID-19; cell-mediated immunity; serology; vaccines; Humans; Aged; COVID-19 Vaccines; Longitudinal Studies; Ad26COVS1; SARS-CoV-2; COVID-19; Viral VaccinesAgedFrontiers in Immunology
researchProduct

Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months

2022

BACKGROUND AND OBJECTIVES On June 4, 2021, Italy launched the coronavirus disease 2019 (COVID-19) vaccination of adolescents to slow down the COVID-19 spread. Although clinical trials have evaluated messenger ribonucleic acid (mRNA) vaccine effectiveness in adolescents, there is limited literature on its real-world effectiveness. Accordingly, this study aimed to estimate the effectiveness of mRNA COVID-19 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mild or severe COVID-19 in a cohort of Sicilian adolescents within a 6 month observation period. METHODS A retrospective cohort study was conducted with adolescents aged 12 to 18 years, residents o…

COVID-19 VaccinesAdolescentSARS-CoV-2Pediatrics Perinatology and Child HealthsurveillanceHumansCOVID-19Viral VaccinesRNA MessengerRetrospective StudiesPediatrics
researchProduct

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

2022

AbstractSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination plays a crucial role as pivotal strategy to curb the coronavirus disease-19 (COVID-19) pandemic. The present study described the clinical status of patients affected by idiopathic inflammatory myopathies (IIM) after COVID-19 vaccination to assess the number of relapses. We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo. They underwent a telephone survey. A total of 119 IIM patients (median, IQR 58 (47–6…

COVID-19 VaccinesMyositisCOVID-19 vaccinationSARS-CoV-2VaccinationCOVID-19Relapses.RecurrenceEmergency MedicineInternal MedicineHumansCOVID-19 vaccination; Idiopathic inflammatory myopathies; RelapsesIdiopathic inflammatory myopathiesIdiopathic inflammatory myopathieRelapses
researchProduct

COVID-19 Vaccination in Pediatric Population: A Necessity or Obstruction to the Protection of the Right to Health? Biojuridical Perspective.

2022

One of the most recently debated topics worldwide is the mass vaccination of children against coronavirus disease 2019 (COVID-19). Next, the risk/benefit ratio of COVID-19 vaccination and infection in children are compared. Nonetheless, the real question in this debate is as follows: Does the vaccine represent a necessary tool or is it an obstacle in protecting the right to health? From a public health point of view, the Supreme Court of Nova Scotia, in Canada, recommends COVID-19 vaccination in the pediatric population. Based on Article 25 of the Draft Articles on State responsibility, vaccination can be considered a social act necessary for protecting the individual's right to health. The…

COVID-19 VaccinesSettore MED/43 - Medicina LegaleRight to Healthcovid 19 vaccination pediatric populationVaccinationPublic Health Environmental and Occupational HealthCOVID-19HumansChildSystemic Inflammatory Response SyndromeFrontiers in public health
researchProduct

Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pande…

2020

Background Starting December 2019, mankind faced an unprecedented enemy, the COVID-19 virus. The world convened in international efforts, experiences and technologies in order to fight the emerging pandemic. Isolation, hygiene measure, diagnosis, and treatment are the most efficient ways of prevention and intervention nowadays. The health organizations and global care systems screened the available resources and offered recommendations of approved and proposed medications. However, the search for a specific selective therapy or vaccine against COVID-19 remains a challenge. Methods A literature search was performed for the screening of natural and derived bio-active compounds which showed po…

COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug Evaluation PreclinicalPharmaceutical ScienceAntiviral AgentsArticle03 medical and health scienceschemistry.chemical_compoundClinical trials0302 clinical medicineTocilizumabChloroquineDrug DiscoveryPandemicmedicineHumansAntiviralPandemics030304 developmental biologyPharmacologyBiological ProductsClinical Trials as TopicNatural products0303 health sciencesProtectionMolecular StructureTraditional medicineSARS-CoV-2business.industryCOVID-19LycorineFingolimodCOVID-19 Drug TreatmentClinical trialConessineComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicinePatentPlant Preparationsbusinessmedicine.drugPhytomedicine
researchProduct

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination

2022

Adverse events occurring after SARS-CoV-2 vaccination have been reported and are the subject of ongoing research. We present the case of a young woman with fully reversible radiculomyelitis, which happened after the first dose of the ChAdOx1 nCOVID-19 vaccine. A previously healthy woman in her 20s presented with a subacute onset of legs’ weakness and sensory disturbances, urinary dysfunction and cramping pain after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. A diagnostic workup led to the diagnosis of inflammatory radiculomyelitis. Her clinical status improved, with complete recovery after a few months. The case described a reversible radiculomyelitis associated with the ChAdOx…

COVID-19 myeloradiculoneuritis case reportCOVID-19 VaccinesSARS-CoV-2ChAdOx1 nCoV-19VaccinationCOVID-19HumansFemaleViral VaccinesSettore MED/26 - NeurologiaGeneral Medicine
researchProduct